sabcs 2022: trio-us b-12 talent: neoadjuvant tdx with or without anastrozole for her2-low, hr e...
Published 1 year ago • 265 plays • Length 17:10Download video MP4
Download video MP3
Similar videos
-
16:12
sabcs 2022: overall survival analysis of the randomized stic ctc trial
-
1:06
sabcs 2022 highlights
-
0:32
highlights in her2-low breast cancer at sabcs 2022
-
12:19
sabcs 2022: updated survival results of the randomized, phase 3 study destiny-breast03 q & a
-
4:08
sabcs 2022 highlights
-
11:35
sabcs 2022: primary results of the randomized, phase 3 study destiny-breast02 q & a
-
1:03
key takeaways from sabcs 2022
-
0:55
key highlights from sabcs 2022
-
0:56
remaining questions on the management of her2-low breast cancer
-
1:25
sabcs 2022: clinical trial highlights
-
17:10
sabcs 2022: results of the randomized, multi-dose phase 2 serena-2 trial
-
5:45
sabcs 2022: prof. dr. med. christoph thomssen, halle (saale): her2-low - eine eigene entität?
-
6:17
sara tolaney, sabcs 2022: adjuvant paclitaxel and trastuzumab for node-negative her2 breast cancer
-
0:51
sabcs 2022: key highlights
-
1:31
discussion highlights from sabcs 2022
-
0:44
what to look out for at sabcs 2022
-
2:00
sabcs 2022 takeaways
-
0:25
copy of dr. shao on managing toxicity with neratinib in her2 breast cancer